Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIHQ5G)

• Drug Name: IL-2/CD40L-expressing leukemia vaccine Drug Info
• Synonyms: Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMIHQ5G

Molecule-Related Drug Atlas

Drug(s) Targeting TNF related activation protein (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[3]
Lucatumumab	DMY2L7V	Lymphoma	2A80-2A86	Phase 2	[4]
Dapirolizumab pegol	DMIYFWA	Systemic lupus erythematosus	4A40.0	Phase 2	[5]
PG-102	DMF5YEN	Autoimmune diabetes	5A10	Phase 2	[6]
ISF35	DMBZK3P	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[7]
CDP-7657	DMN8I5Q	Systemic lupus erythematosus	4A40.0	Phase 1	[8]
MEDI4920	DME7BMT	Rheumatoid arthritis	FA20	Phase 1	[9]
UltraCD40L	DMHG7DZ	Systemic lupus erythematosus	4A40.0	Phase 1	[10]
BPX-101	DM51MSD	Prostate cancer	2C82.0	Phase 1	[11]
Chi Lob 7/4	DMSOB5D	B-cell lymphoma	2A86	Phase 1	[12]

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[13]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[14]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[15]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[16]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[17]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[18]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[19]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[20]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[21]
Thymoctonan	DM4BLJM	Immune System disease	4A01-4B41	Phase 2	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Not Available	[2]
TNF related activation protein (CD40LG)	TTIJP3Q	CD40L_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01604031) Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide. U.S. National Institutes of Health.
• [2] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [3] FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
• [4] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
• [7] Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
• [8] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
• [9] ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
• [10] CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
• [11] Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
• [12] Agonistic CD40 antibodies and cancer therapy
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [15] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [16] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [17] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [18] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [19] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [20] Clinical pipeline report, company report or official report of Immunservice.
• [21] National Cancer Institute Drug Dictionary (drug id 665656).
• [22] Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.